|
Mutation Information
|
Mutation Site
|
M204I |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Relevant Drug
|
lamivudine (LAM) |
|
Country
|
Taiwan;China |
Literature Information
|
PubMed PMID
|
22156858
|
|
Disease
|
HBV-HIV coinfection
|
|
Published Year
|
2012 |
|
Journal
|
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |
|
Title
|
Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy. |
|
Author
|
Sheng WH,Hung CC,Chang SY,Liu CJ,Chen MY,Hsieh SM,Kao JH,Chen PJ,Chang SC |
|
Evidence
|
Clinical and immunologic outcomes in the context of HBV genotypes as well as the emergence of HBV DNA mutations conferring lamivudine resistance (rtM204I/V) were determined.
|
|
|
HBV Mutation Detail Information